Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

Table 1 Treatment sequence regimens

Treatment sequence	Period 1	Interval between dosing	Period 2	Interval between dosing	Period 3
Treatment sequence	3 Days	2 to 15 days	3 days	2 to 15 days	3 days
1	A	Continue metformin only	C	Stop all trial medications	B
2	C	Continue metformin only	A	Stop all trial medications	B

Treatment A (MET BID): Metformin IR 500 mg every 12 hours. Treatment B (RE BID): Remogliflozin etabonate 500 mg every 12 hours. Treatment C (MET + RE BID): Metformin IR 500 mg every 12 hours + remogliflozin etabonate 500 mg every 12 hours. Metformin was administered starting from the morning of Day 1 of Period 1 and stopped after the morning dose on Day 3 of Period 2. For any Treatment Period when remogliflozin etabonate was administered, remogliflozin etabonate dosing was stopped after the morning dose was given on Day 3.

ISSN: 2050-6511